allogeneic

Type: Keyphrase
Name: allogeneic
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Allogeneic Conditioning Regimen Reduces Myelosuppression, Graft-vs-Host Disease in Lymphocytic Leukemia/Lymphoma

By Charlotte BathSeptember 15, 2014, Volume 5, Issue 15The combination of bendamustine (Treanda), fludarabine, and rituximab (Rituxan), or BFR, was shown to be safe and effective conditioning for patients with relapsed chronic lymphocytic leukemia/lymphoma ... [Published The ASCO Post - 6 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Form: Non-technical summaries granted during 2013: volume 38

The following projects are listed in volume 38 of 2013:rodent regulatory genotoxicity (covering cytoxicity, rodents) non-clinical studies in domestic livestock species (covering safety, efficacy, surgical models, livestock species) role of inflammation ... [Published Cabinet Office - 11 hours ago]
First reported 18 hours ago - Updated 15 hours ago - 1 reports

TiGenix: TiGenix to participate or present at key conferences in the second half of 2014

LEUVEN, Belgium, Sept. 15, 2014 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived ... [Published Wall Street Business Network - 18 hours ago]
First reported Sep 15 2014 - Updated 20 hours ago - 1 reports

MEDIPOST America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung

ROCKVILLE, Md.--(BUSINESS WIRE)--MEDIPOST America Inc. (CEO: Dr. Antonio Lee) today announced the US FDA approval of Phase 1/2 clinical trial for PNEUMOSTEM®. The Phase 1/2 trial will assess the safety and efficacy of PNEUMOSTEM® on prematurely born infants ... [Published Business Wire Health News - Sep 15 2014]
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

Prolonging Survival of Corneal Transplantation by Selective Sphingosine-1-Phosphate Receptor 1 Agonist

by Min Gao, Yong Liu, Yang Xiao, Gencheng Han, Liang Jia, Liqiang Wang, Tian Lei, Yifei HuangCorneal transplantation is the most used therapy for eye disorders. Although the cornea is somewhat an immune privileged organ, immune rejection is still the ... [Published Plosone.org - Sep 13 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Pluristem Therapeutics (PSTI) Releases Quarterly Earnings, Beats Estimates By $0.06 EPS

Pluristem Therapeutics (NASDAQ:PSTI) posted its quarterly earnings results on Thursday. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.06, reports. On the ratings front, analysts ... [Published American Banking News - Forex - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Cellerant Awarded $47.5M Under U.S. Contract

Cellerant Therapeutics Inc. has been awarded $47.5 million under a second option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of ... [Published Contract Pharma - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 1 reports

University of Cologne Details Findings in Stem Cells (Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies....

University of Cologne Details Findings in Stem Cells (Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German ...)By a News ... [Published HispanicBusiness.com - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

After FDA Approval, Duchenne’s Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the United States

Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctor’s application for a single patient, ... [Published Bio-Medicine - Sep 10 2014]
First reported Sep 04 2014 - Updated Sep 05 2014 - 2 reports

Cellectis completes sale of its Swedish subsidiary to Takara Bio

Cellectis, a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART), has closed the sale of its subsidiary Cellectis AB to Takara Bio Inc.,  an innovative biotechnology company based in Shiga, Japan. The ... [Published PharmaBiz - Sep 05 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Langerhans Cell Homeostasis and Turnover After Nonmyeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation

BackgroundLangerhans cells (LCs) are self-renewing epidermal myeloid cells that can migrate and mature into dendritic cells. Recipient LCs that survive cytotoxic therapy given in preparation for allogeneic hematopoietic cell transplantation may prime ... [Published Transplantation - Sep 02 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 2 reports

Stemedica International Announces Pre-clinical Data Of Its Alzheimer???s Study

EPALINGES, Switzerland--(BUSINESS WIRE)--Stemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, ... [Published BioSpace - Aug 20 2014]

Quotes

"The exercise of this second option reflects recognition of the importance of this first-in-kind therapy to serve an unmet medical need to reduce the infection-related complications from severe neutropenia caused by chemotherapy or exposure to radiation" Mandalam said
"I want so badly for every parent, once their kid is diagnosed with a disease like mine, to be able to just go get treated," he said. "It would be something that 20 years later the kid says to the parent, 'Didn't I have muscular dystrophy when I was younger?' The parent would say 'Ya, you did, but we got it treated.' That would be amazing to me."
"We are pleased that the federal government continues to support our efforts in this successful public-private partnership with BARDA" said Ram Mandalam, Ph D , president and chief executive officer of Cellerant...
Pedro Lichtinger, Asterias' chief executive officer, said: "The Asterias collaboration with Cancer Research UK's Drug Development Office and CRT represents a major step in advancing our proprietary dendritic cell platform for the potential benefit of patients."

More Content

All (289) | News (211) | Reports (0) | Blogs (69) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Allogeneic Conditioning Regimen Reduces Myelosu... [Published The ASCO Post - 6 hours ago]
Potential new treatment for GVHD [Published Australian Life Scientist - 8 hours ago]
Pluristem Therapeutics Given New $3.00 Price Ta... [Published Mideast Time - 8 hours ago]
‘Paradigm-Shifting’ Results in Treatment of Hem... [Published The ASCO Post - 9 hours ago]
UK cancer charity partners with Asterias Biothe... [Published Pharma Letter - 10 hours ago]
Form: Non-technical summaries granted during 20... [Published Cabinet Office - 11 hours ago]
Jefferies Group Cuts Pluristem Therapeutics Pri... [Published American Banking News - Forex - 15 hours ago]
TiGenix: TiGenix to participate or present at k... [Published Wall Street Business Network - 18 hours ago]
Sarcoid-Associated Pulmonary Hypertension and L... [Published General Medicine eJournal - 20 hours ago]
MEDIPOST America clears Phase 1/2 IND for the U... [Published Investor's Business Daily - 20 hours ago]
MEDIPOST America clears Phase 1/2 IND for the U... [Published Finwin - Sep 15 2014]
MEDIPOST America clears Phase 1/2 IND for the U... [Published Crawford Financial Planning - Sep 15 2014]
MEDIPOST America clears Phase 1/2 IND for the U... [Published Business Wire Health News - Sep 15 2014]
Cellerant awarded $47.5M for development of CLT... [Published Center Watch - Sep 13 2014]
Cellerant gets $47.5m contract to support devel... [Published Pharmaceutical Business Review - Sep 13 2014]
Prolonging Survival of Corneal Transplantation ... [Published Plosone.org - Sep 13 2014]
Pluristem Therapeutics (PSTI) Releases Quarterl... [Published American Banking News - Forex - Sep 12 2014]
Global Bone Marrow Transplantation Therapeutics... [Published Individual.com - Sep 12 2014]
Wichita man receives first umbilical cord stem ... [Published KWCH 12 - Sep 12 2014]
Cellerant Awarded $47.5M Under U.S. Contract [Published Contract Pharma - Sep 11 2014]
BioTime Subsidiary, Asterias Biotherapeutics, a... [Published EON Science - Sep 11 2014]
BioTime Subsidiary, Asterias Biotherapeutics, a... [Published Business Wire Science: Science News - Sep 11 2014]
BioTime Subsidiary, Asterias Biotherapeutics, a... [Published Business Wire Health News - Sep 11 2014]
Cellerant Awarded $47.5M Under Existing Contrac... [Published PharmaceuticalProcessing - Sep 11 2014]
Greater need for bone marrow donors in SA [Published FAnews - Sep 11 2014]
Cellerant Awarded $47.5 Million Under Existing ... [Published Industrial Info Financials - Sep 11 2014]
Cancer Research UK, CRT partner with Asterias t... [Published News-Medical.Net - Sep 11 2014]
Cancer Research UK, Cancer Research Technology ... [Published Bio-Medicine - Sep 11 2014]
Cancer Research UK, Cancer Research Technology ... [Published Nasdaq - Sep 11 2014]
Cancer Research UK, Cancer Research Technology ... [Published RCL Advisors - Sep 11 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
MEDIPOST America clears Phase 1/2 IND for the U... [Published Business Wire Health News - Sep 15 2014]
ROCKVILLE, Md.--(BUSINESS WIRE)--MEDIPOST America Inc. (CEO: Dr. Antonio Lee) today announced the US FDA approval of Phase 1/2 clinical trial for PNEUMOSTEM®. The Phase 1/2 trial will assess the safety and efficacy of PNEUMOSTEM® on prematurely born infants ...
BioTime Subsidiary, Asterias Biotherapeutics, a... [Published EON Science - Sep 11 2014]
ALAMEDA, Calif.--(EON: Enhanced Online News)--BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s ...
BioTime Subsidiary, Asterias Biotherapeutics, a... [Published Business Wire Science: Science News - Sep 11 2014]
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s development ...
BioTime Subsidiary, Asterias Biotherapeutics, a... [Published Business Wire Health News - Sep 11 2014]
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) announced that its subsidiary Asterias Biotherapeutics, Inc. (OTCBB: ASTY) has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s development ...
BloodCenter of Wisconsin Launches Erythroid Chi... [Published PR Newswire: Policy & Public Interest - Aug 28 2014]
MILWAUKEE, Aug. 28, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of an innovative Erythroid Chimerism test to monitor erythroid lineage chimerism in patients with sickle cell disease ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
TiGenix Business and Financial Update for the F... [Published GlobeNewswire: Acquisitions News - Aug 26 2014]
Cesca Therapeutics and Fortis Healthcare Announ... [Published GlobeNewswire: Acquisitions News - Aug 05 2014]
TiGenix announces the clinical development of C... [Published GlobeNewswire: Advertising News - Jun 30 2014]
Immunicum’s abstract with data from a kidney ca... [Published GlobeNewswire: Acquisitions News - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.